Scotiabank Reaffirms Buy Rating on Johnson & Johnson at $305

Scotiabank analyst Louise Chen has maintained her 'Buy' rating on Johnson & Johnson, setting a price target of $305.00.

This recommendation is part of Chen's coverage of the Healthcare sector, where she focuses on companies like Gilead Sciences and Merck & Company.

J&J recently reported quarterly revenue of $25.31 billion and a net profit of $5.53 billion for the period ending June 28.

However, corporate insider activity suggests that sentiment may be turning negative on the stock, with 37 insiders selling shares over the past quarter compared to earlier this year.